Evidence map›Paper›PMID 35327371›Full record

ArticleBiomedicines2022

The Proteome of Antibody-Mediated Rejection: From Glomerulitis to Transplant Glomerulopathy.

Bertrand Chauveau, Anne-Aurélie Raymond, Sylvaine Di Tommaso, Jonathan Visentin, Agathe Vermorel, Nathalie Dugot-Senant, Cyril Dourthe, Jean-William Dupuy, Julie Déchanet-Merville, Jean-Paul Duong Van Huyen and 4 more

Open access · goldAbstract read
In one paragraph

Article in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Bertrand ChauveauCHU de Bordeaux, Service de Pathologie, Hôpital Pellegrin, Place Amélie Raba Léon, F-33000 Bordeaux, France.ORCID 0000-0002-3250-4604
Anne-Aurélie RaymondPlateforme Oncoprot, TBM-Core US 005, Université Bordeaux, F-33000 Bordeaux, France.ORCID 0000-0003-2697-9352
Sylvaine Di TommasoPlateforme Oncoprot, TBM-Core US 005, Université Bordeaux, F-33000 Bordeaux, France.ORCID 0000-0003-4507-2844
Jonathan VisentinImmunoConcEpT, CNRS, Université Bordeaux, UMR 5164, 146 Rue Léo Saignat, F-33000 Bordeaux, France.
Agathe VermorelCHU de Bordeaux, Service de Néphrologie, Transplantation Dialyse, Aphérèses, Hôpital Pellegrin, Place Amélie Raba Léon, F-33000 Bordeaux, France.
Nathalie Dugot-SenantPlateforme d'Histopathologie, TBM-Core US 005, Université Bordeaux, F-33000 Bordeaux, France.
Cyril DourthePlateforme Oncoprot, TBM-Core US 005, Université Bordeaux, F-33000 Bordeaux, France.
Jean-William DupuyPlateforme Protéome, Université Bordeaux, F-33000 Bordeaux, France.ORCID 0000-0002-2448-4797
Julie Déchanet-MervilleImmunoConcEpT, CNRS, Université Bordeaux, UMR 5164, 146 Rue Léo Saignat, F-33000 Bordeaux, France.
Jean-Paul Duong Van HuyenAssistance Publique-Hôpitaux de Paris (AP-HP), Service de Pathologie, Hôpital Necker, F-75015 Paris, France.
Marion RabantAssistance Publique-Hôpitaux de Paris (AP-HP), Service de Pathologie, Hôpital Necker, F-75015 Paris, France.
Lionel CouziImmunoConcEpT, CNRS, Université Bordeaux, UMR 5164, 146 Rue Léo Saignat, F-33000 Bordeaux, France.
Frédéric SaltelPlateforme Oncoprot, TBM-Core US 005, Université Bordeaux, F-33000 Bordeaux, France.
Pierre MervilleImmunoConcEpT, CNRS, Université Bordeaux, UMR 5164, 146 Rue Léo Saignat, F-33000 Bordeaux, France.ORCID 0000-0001-8987-2929
Centre National de la Recherche Scientifique · FRInserm · FRHôpital Necker-Enfants Malades · FRUniversité de Bordeaux · FRCentre Hospitalier Universitaire de Bordeaux · FR

Funding

France Rein Aquitaine 2020 grantFrancophone Society of Transplantation 2019 grant, clinical research category
6 · The paper itself

Abstract

Antibody-mediated rejection (ABMR) is the leading cause of allograft failure in kidney transplantation. Its histological hallmark is represented by lesions of glomerulitis i.e., inflammatory cells within glomeruli. Current therapies for ABMR fail to prevent chronic allograft damage i.e., transplant glomerulopathy, leading to allograft loss. We used laser microdissection of glomeruli from formalin-fixed allograft biopsies combined with mass spectrometry-based proteomics to describe the proteome modification of 11 active and 10 chronic active ABMR cases compared to 8 stable graft controls. Of 1335 detected proteins, 77 were deregulated in glomerulitis compared to stable grafts, particularly involved in cellular stress mediated by interferons type I and II, leukocyte activation and microcirculation remodeling. Three proteins extracted from this protein profile, TYMP, WARS1 and GBP1, showed a consistent overexpression by immunohistochemistry in glomerular endothelial cells that may represent relevant markers of endothelial stress during active ABMR. In transplant glomerulopathy, 137 proteins were deregulated, which favor a complement-mediated mechanism, wound healing processes through coagulation activation and ultimately a remodeling of the glomerular extracellular matrix, as observed by light microscopy. This study brings novel information on glomerular proteomics of ABMR in kidney transplantation, and highlights potential targets of diagnostic and therapeutic interest.

Indexed as

antibody-mediated rejectionglomeruluskidney transplantationproteomicstransplant glomerulopathy

Identifiers

PMID35327371
PMCPMC8945687
OpenAlexW4214559884

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.